Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Business
Impacts Of The Covid-19 Pandemic On Business Education: Case For The Aacsb’S Agility Standard, Lucy Ojode, Mulugeta Wolde, June Claiborne
Impacts Of The Covid-19 Pandemic On Business Education: Case For The Aacsb’S Agility Standard, Lucy Ojode, Mulugeta Wolde, June Claiborne
Southwestern Business Administration Journal
We explored an undergraduate business program’s navigation of an unplanned change, response to the Covid-19 pandemic-occasioned move to online learning, and the resilience of its curriculum by following cohorts of students through two consecutive courses from the end of 2019 through 2020 up to summer 2021. The exploration was aimed at the assessment of the impact of the pandemic-induced disruptions, i.e., how the school’s curriculum fared through the pandemic. Premised on the school’s accreditor, AACSB’s agility-cultivating curriculum guideline, the curriculum should adapt and stabilize post-pandemic. To identify the appropriate cohort for observation, we scrutinized the four progressive levels of agility …
An Analysis Of Covid-19 Vaccine Allergic Reactions, Robert Schumaker, Michael Veronin, Trevor Rohm, Rohit Dixit, Shadi Aljawarneh, Juan Lara
An Analysis Of Covid-19 Vaccine Allergic Reactions, Robert Schumaker, Michael Veronin, Trevor Rohm, Rohit Dixit, Shadi Aljawarneh, Juan Lara
Journal of International Technology and Information Management
From our study, all three covid-19 vaccines have a similar proportion of adverse reaction reports in which the patient had a history of allergies. However, the proportion of life-threatening outcomes were lower for those with the Janssen vaccine (0.62% hospitalization rate for Janssen versus 2.59% for Pfizer and 0.60% death for Janssen versus 5.15% for Moderna). In terms of specific allergies, patients with *cillin or sulfa allergies had the most adverse reactions to covid-19 vaccines, however, Janssen again had the lowest percentage of reported deaths (1.39% for *cillin-related allergy deaths for Janssen versus 6.10% for Pfizer). In terms of patient …